BioTime, Inc. (BTX)

Check out top investors' recommendation for BTX
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
N/A
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
N/A
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
BioTime, Inc., a biotechnology company, focuses on regenerative medicine and blood plasma volume expanders. The company primarily focuses on regenerative medicine, which refers to therapies based on human embryonic stem cell and induced pluripotent stem cell technology designed to rebuild cell and tissue function lost due to degenerative disease or injury. It develops and markets research products in the field of stem cells, including an array of proprietary PureStem cell lines and associated ESpan culture media, HyStem hydrogels, and differentiation kits, as well as offers Hextend, a blood plasma volume expander. The company is developing Renevia, a biocompatible, implantable hyaluronan, and collagen-based matrix for cell delivery in human clinical applications; stem cell-based therapies for retinal and neural degenerative diseases; and therapies to treat orthopedic disorders, diseases, and injuries. It is also developing PanC-Dx, a non-invasive blood-based cancer screening test; and therapeutic products for cardiovascular and blood diseases and disorders. In addition, the company markets GeneCards, a human gene database. Further, it is developing an integrated database suite to complement GeneCards that would include the LifeMap database of embryonic development, stem cell research, and regenerative medicine, as well as MalaCards, the human disease database. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Kevin Degeeter Ladenburg Thalmann & Co. Buy   Mar 14, '19     3.00  Mar 14, '20  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Feb 21, '19     4.00  Feb 21, '20  N/A 
Kevin Degeeter Ladenburg Thalmann & Co. Buy   Jan 29, '19     3.50  Jan 29, '20  N/A 
Bruce Jackson Northland Sec Buy   Feb 02, '18     8.00  Feb 02, '19  N/A 
Keay Nakae Ascendiant Capital Markets Buy   Feb 19, '16   2.19  5.00  Feb 19, '17  35.62% 
Ling Wang Summer Street Research Buy   Dec 22, '15   4.18  10.00  Dec 22, '16  -10.53% 
Stephen Brozak WBB Securities, LLC Buy   Dec 18, '11   4.31  8.00  Dec 18, '12  -18.33% 
Stephen Brozak WBB Securities, LLC Buy   Nov 15, '11   4.52  8.00  Nov 15, '12  -34.29% 
Stephen Brozak WBB Securities, LLC Buy   Aug 10, '11   4.47  6.00  Aug 10, '12  34.23%